Literature DB >> 22265587

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Bradley T Hyman1, Creighton H Phelps, Thomas G Beach, Eileen H Bigio, Nigel J Cairns, Maria C Carrillo, Dennis W Dickson, Charles Duyckaerts, Matthew P Frosch, Eliezer Masliah, Suzanne S Mirra, Peter T Nelson, Julie A Schneider, Dietmar Rudolf Thal, Bill Thies, John Q Trojanowski, Harry V Vinters, Thomas J Montine.   

Abstract

A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre-clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP-43 inclusions, and recommend standard approaches for the workup of cases and their clinico-pathologic correlation.
Copyright © 2012 The Alzheimer's Association. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22265587      PMCID: PMC3266529          DOI: 10.1016/j.jalz.2011.10.007

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  106 in total

Review 1.  Cerebral amyloid angiopathy and Alzheimer's disease: two entities or one?

Authors:  H V Vinters
Journal:  J Neurol Sci       Date:  1992-10       Impact factor: 3.181

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Pathological markers associated with normal aging and dementia in the elderly.

Authors:  H A Crystal; D W Dickson; M J Sliwinski; R B Lipton; E Grober; H Marks-Nelson; P Antis
Journal:  Ann Neurol       Date:  1993-10       Impact factor: 10.422

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital.

Authors:  C Bouras; P R Hof; P Giannakopoulos; J P Michel; J H Morrison
Journal:  Cereb Cortex       Date:  1994 Mar-Apr       Impact factor: 5.357

6.  Diffuse neurofibrillary tangles with calcification: a new presenile dementia.

Authors:  K Kosaka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

7.  Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease.

Authors:  E Masliah; M Mallory; T Deerinck; R DeTeresa; S Lamont; A Miller; R D Terry; B Carragher; M Ellisman
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

8.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease.

Authors:  M Gearing; S S Mirra; J C Hedreen; S M Sumi; L A Hansen; A Heyman
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

9.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

Authors:  D W Dickson; H A Crystal; L A Mattiace; D M Masur; A D Blau; P Davies; S H Yen; M K Aronson
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

10.  Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene.

Authors:  S R Dlouhy; K Hsiao; M R Farlow; T Foroud; P M Conneally; P Johnson; S B Prusiner; M E Hodes; B Ghetti
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

View more
  887 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Mild to moderate Alzheimer dementia with insufficient neuropathological changes.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Deborah Blacker; Teresa Gómez-Isla; Rebecca A Betensky; John H Growdon; Keith A Johnson; Matthew P Frosch; Reisa A Sperling; Bradley T Hyman
Journal:  Ann Neurol       Date:  2014-04-08       Impact factor: 10.422

Review 3.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

4.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Authors:  Dustin W Wooten; Nicolas J Guehl; Eline E Verwer; Timothy M Shoup; Daniel L Yokell; Nevena Zubcevik; Neil Vasdev; Ross D Zafonte; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

5.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

6.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

Review 7.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 8.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

9.  Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Authors:  Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte
Journal:  Mol Cell Neurosci       Date:  2017-04-21       Impact factor: 4.314

Review 10.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.